Pyra­mid inks TROP2 pact with Chi­na biotech to fol­low suit of Gilead, As­traZeneca-Dai­ichi Sankyo

Look­ing to go where Gilead al­ready is and where As­traZeneca-part­nered Dai­ichi Sankyo is head­ed, Pyra­mid Bio­sciences has locked in a pact for a TROP2-tar­get­ed an­ti­body-drug con­ju­gate.

The Bridge­wa­ter, NJ biotech is link­ing up with Chi­na-based GeneQuan­tum Health­care to gain ac­cess to GQ1010, which will en­ter a glob­al clin­i­cal tri­al with­in 12 months, the com­pa­nies said Thurs­day.

The deal marks an ex­pand­ed fo­cus in on­col­o­gy for Pyra­mid, where it al­ready has a Phase I for an­oth­er as­set, and as it looks to part­ner out a Phase II-ready der­ma­tol­ogy drug can­di­date with a bio­phar­ma in that space, CEO Bri­an Les­ti­ni told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER